Los fundamentos de Schrodinger Inc son relativamente muy saludable,y su potencial de crecimiento es significativo.Su valoración está considerada valorada de forma justa, ranking 79 de 486 en la industria de Servicios de software e informática.Su propiedad institucional es muy alto.Durante el último mes, varios analistas lo han calificado como Compra, con el precio objetivo más alto en 19.57.A medio plazo, se espera que el precio de la acción tienda al alza.La empresa ha obtenido buenos resultados en bolsa durante el último mes, y esto se ve respaldado por sus fundamentos y datos técnicos sólidos.Las acciones se mantienen sin una tendencia clara entre los niveles de soporte y resistencia, así que son adecuadas para el swing trading en un mercado lateral.
Puntuación de Schrodinger Inc
Información Relacionada
Ranking de la industria
79 / 486
Clasificación general
139 / 4565
Industria
Servicios de software e informática
Resistencia y Soporte
La empresa aún no ha revelado los datos relevantes.
Gráfico de radar
Precio actual
Anterior
Cobertura mediática
Últimas 24 horas
Nivel de cobertura
Muy bajo
Muy alto
Neutro
Aspectos destacados de Schrodinger Inc
Puntos fuertesRiesgo
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.
Alto crecimiento
Los ingresos de la empresa han crecido de manera constante durante los últimos tres años, con un promedio interanual del 18.09%.
Infravalorada
El PE más reciente de la empresa es -12.07, en un rango percentil bajo de 3 años.
Venta institucional
Las tenencias institucionales más recientes son 71.93M acciones, lo que supone una reducción del 9.13% con respecto al trimestre anterior.
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.